TOLERABILITY OF FIBRIC ACIDS - COMPARATIVE DATA AND BIOCHEMICAL-BASES

被引:16
作者
SIRTORI, CR
CALABRESI, L
WERBA, JP
FRANCESCHINI, G
机构
[1] Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, 20133 Milano
关键词
FIBRATES; LITHOGENICITY; ACUTE MUSCULAR SYNDROME; DIABETES; FIBRINOLYSIS;
D O I
10.1016/1043-6618(92)90212-T
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fibric acids are an established class of drugs for the treatment of hyperlipoproteinaemias. Although they have been in use for 30 years or longer, some doubts remain as to their relative tolerability, both as a class and as single agents. Some side effects, e.g. lithogenicity, may be related to their mode of action, while others, e.g. the acute muscular syndrome, may be linked to the spatial conformation of the molecule. These disadvantages should, however, be weighed against the additional, potentially therapeutic properties shown by these compounds. In particular, effects on maturity onset diabetes and hyperuricaemia, as well as a very interesting fibrinolysic potential, have been described for some of them. A painstaking comparative analysis of the major literature data pertaining to the clinical toxicological profile of these agents allow to conclude that, while belonging to a chemical class, fibric acids show dramatic differences from one another, in terms of side effects and of additional pharmacodynamic activities. Moreover, in the case of lithogenicity for example, considerable differences exist between normo- and hyperlipidaemic subjects. Overall, newer molecules of more sophisticated design have a significantly improved tolerability profilevs the old clofibrate. © 1992 The Italian Pharmacological Society.
引用
收藏
页码:243 / 260
页数:18
相关论文
共 81 条
[41]   EVALUATION OF SELECTED HYPOLIPIDEMIC AGENTS FOR THE INDUCTION OF PEROXISOMAL ENZYMES AND PEROXISOME PROLIFERATION IN THE RAT-LIVER [J].
LALWANI, ND ;
REDDY, MK ;
QURESHI, SA ;
SIRTORI, CR ;
ABIKO, Y ;
REDDY, JK .
HUMAN TOXICOLOGY, 1983, 2 (01) :27-48
[42]   ACUTE MUSCULAR SYNDROME ASSOCIATED WITH ADMINISTRATION OF CLOFIBRATE [J].
LANGER, T ;
LEVY, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1968, 279 (16) :856-&
[43]  
LEISS O, 1986, J LIPID RES, V27, P713
[44]   EFFECT OF GEMFIBROZIL ON BILIARY LIPID-METABOLISM IN NORMOLIPEMIC SUBJECTS [J].
LEISS, O ;
VONBERGMANN, K ;
GNASSO, A ;
AUGUSTIN, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1985, 34 (01) :74-82
[45]   RHABDOMYOLYSIS AND ACUTE-RENAL-FAILURE INDUCED BY COMBINATION LOVASTATIN AND GEMFIBROZIL THERAPY [J].
MARAIS, GE ;
LARSON, KK .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (03) :228-230
[46]  
MARCUS EL, 1982, ATHEROSCLEROSIS, V43, P19
[47]   HEMOSTATIC FUNCTION AND ISCHEMIC-HEART-DISEASE - PRINCIPAL RESULTS OF THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
BROZOVIC, M ;
CHAKRABARTI, RR ;
HAINES, AP ;
IMESON, JD ;
MELLOWS, S ;
MILLER, GJ ;
NORTH, WRS ;
STIRLING, Y ;
THOMPSON, SG .
LANCET, 1986, 2 (8506) :533-537
[48]   PLASMA TISSUE PLASMINOGEN-ACTIVATOR INHIBITOR LEVELS IN CORONARY-ARTERY DISEASE - CORRELATION WITH AGE AND SERUM TRIGLYCERIDE CONCENTRATIONS [J].
MEHTA, J ;
MEHTA, P ;
LAWSON, D ;
SALDEEN, T .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (02) :263-268
[49]  
MOODY DE, 1978, AM J PATHOL, V90, P435
[50]   EFFECT OF CLOFIBRATE ON POSTHEPARIN PLASMA TRIGLYCERIDE LIPASE ACTIVITIES IN PATIENTS WITH HYPERTRIGLYCERIDEMIA [J].
NIKKILA, EA ;
HUTTUNEN, JK ;
EHNHOLM, C .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1977, 26 (02) :179-186